A working list of trials in the United States that are recruiting or about to open for an adult with glioblastoma, IDH-wildtype, DNA-methylation class “GBM, RTK II” (the EGFR / classical family). Each entry shows how the trial is run, who can enrol, what results exist so far, where it runs, and how it fits a treatment-naïve patient whose 1.2 cm tumour was fully resected.
Companion pages — Neoantigen & Personalized Peptide Vaccine Atlas: the same patient, focused entirely on vaccines built from the tumour’s own mutations (or a per-patient peptide selection), with a worldwide trials section and a section on private providers that sell this outside a trial. · Treatment-Optimization Atlas: now that a real plan is set (chemoradiation, a Duke immunotherapy trial, CeGaT as supportive treatment), a toggleable timeline with a live, literature-based optimization score for every adjunct and repurposed drug under consideration.
Static reference page: no account, no login, no forms or input fields; it collects and transmits nothing, sells nothing, and is not affiliated with, nor endorsed by, any clinic, company, hospital or trial named. Clinic and company names are shown as plain text, not links.
13 trials are currently recruiting and match the filters below: adult, IDH-wildtype glioblastoma, at least one US site, an immunotherapy or EGFR-targeted mechanism, open to newly diagnosed disease, and not gated on an MGMT-unmethylated requirement (6 trials that required it were moved to their own section near the bottom of this page for this case). 4 more trials exist but are not currently recruiting — moved to their own section below the matched list so this page's primary list stays limited to what you could actually enrol in today. A re-scrub of the full ClinicalTrials.gov registry on 5 September 2026 found one trial the original search had missed (TGX-007, NCT07346144) — added below.
Because the 1.2 cm tumour is already fully removed, trials that need tumour tissue still in the brain (a planned biopsy-then-resection, or a drug/wafer placed during surgery) are generally not open to this patient now unless disease recurs.
“Standard archival tissue” means the paraffin block any resection already produces is enough — no special banking action was needed at surgery. The fresh / viable / fresh-frozen categories are the ones worth confirming with the surgical/pathology team right away.
RTK II is a DNA-methylation class of IDH-wildtype glioblastoma, sitting in the EGFR / “classical” family. These tumours very often carry EGFR gene amplification, sometimes the EGFRvIII rearrangement or an EGFR point mutation, usually with CDKN2A/B loss and chromosome 7 gain / chromosome 10 loss.
Almost no trial enrols by methylation class. What actually drives trial matching:
Reality check on the class: EGFR-targeted drugs have repeatedly failed in unselected glioblastoma (systemic cetuximab; the depatuxizumab-mafodotin antibody-drug conjugate in the randomised INTELLANCE-1 trial). Checkpoint inhibitors alone were negative in newly diagnosed disease (CheckMate-498, CheckMate-548). The current trials bet on brain-penetrant drugs, better patient selection, and combinations. No immunotherapy or EGFR-targeted approach is yet standard of care for newly diagnosed glioblastoma.
Sorted by how well the trial fits this specific case. “Fit” is a rough editorial judgement, not a medical opinion — read the detail and confirm with the study team.
Evidence score rates how much clinical outcome data stands behind the approach so far: 5/5 positive randomised phase 3 · 4/5 positive randomised phase 2 · 3/5 single-arm survival signal vs historical · 2/5 early biological or radiographic signal, survival immature · 1/5 first-in-human, no outcomes yet · ⚠ caution a prior pivotal trial of this approach was negative. Every trial links to its ClinicalTrials.gov record and, where they exist, the publications behind it. The score is not a prediction for this patient.
Same eligibility fit as the matched list above (adult, IDH-wildtype GBM, newly diagnosed, not gated on MGMT-unmethylated status), but not open for enrolment right now — either “not yet recruiting” (worth checking back on) or with US sites listed as closed. Moved here so the primary list above stays limited to what you could actually enrol in today.
Otherwise similar fit (adult, IDH-wildtype GBM, newly diagnosed, ≥1 US site), but every trial below requires MGMT-promoter-unmethylated status specifically. MGMT status came back methylated on 11 Sep 2026 — these 6 are now confirmed genuinely excluded, not just excluded pending confirmation as originally noted. Kept here, not deleted, in case that ever needs rechecking (e.g. a different sample, or at recurrence).
These determine which trials are realistically open. Tick them off as they are answered.
Clinics that manufacture a personalised cell product — a dendritic-cell vaccine made from the patient’s own tumour tissue, or expanded/activated NK and T cells — and sell it directly to patients, generally outside any registered clinical trial. This is a fundamentally different category from every trial above: not FDA- or EMA-approved, not randomised, evidence is almost always a small case series or none at all, and it is paid for out of pocket (commonly USD/EUR tens of thousands). Included for completeness because they were asked for — not as a recommendation.
| Provider | Contact | What is manufactured | Starting material | Regulatory framework | Est. cost | Insurance | Evidence | Patient story | Caution |
|---|---|---|---|---|---|---|---|---|---|
| IOZK Cologne, Germany |
iozk.de +49 221 4203 9925 |
IO-Vac® autologous dendritic-cell vaccine, matured with oncolytic Newcastle disease virus — drives T-cell (and NK) activation against the patient’s own tumour antigens. | Tumour tissue (autologous lysate) + blood (monocyte-derived dendritic cells) | German “individual healing attempt” (Heilversuch) / hospital exemption — legal, not an efficacy approval | ~€23,000–26,000 per vaccination cycle (≥2 cycles typically needed); ~€65,000 for the first two cycles + mandatory diagnostics (€6,800–8,500). A 5-day immunogenic-cell-death add-on runs €6,000–11,000 more. | German statutory insurance rarely covers this without dispute; private German insurers sometimes reimburse partially, case-by-case, occasionally only after appeal or court order when standard options are exhausted. Not billed to non-German (e.g. US) insurance. | Published single-institution case series in IDH-wildtype GBM reporting improved OS vs historical published data — PMC 2023. Not randomised. | None currently listed. | Of the group here, the most documented in peer-reviewed literature specifically for GBM. Still not a controlled trial; ask for the full published methodology and an independent read of the survival comparison. |
| Seren Clinic & Osaka ISEIKAI Clinic Tokyo, Fukuoka, Nagoya, Kobe, Osaka — Japan |
serenclinic.jp Seren: 0120-784-788 meneki-clinic.jp (Osaka ISEIKAI contact form) |
Peptide/tumour-antigen-pulsed dendritic-cell vaccines; some delivered via the J-SICT multi-centre compassionate-use network. | Tumour tissue or defined tumour antigens (varies by protocol) + blood | Japan Act on the Safety of Regenerative Medicine — government-reviewed safety framework, not an efficacy review | ¥44,000–66,000 (~USD 300–450) per antigen is published; total course cost (multiple doses/antigens over weeks) is not publicly listed — request a full itemised quote. | Classified as “Advanced Medical Care” in Japan — approved for safety but not funded by Japan’s National Health Insurance for general use, and not covered by foreign/international insurance. Fully out-of-pocket. | Compassionate-use case reporting only; no randomised glioblastoma survival/efficacy data located. An independent study of patient experience at this class of Japanese DC-vaccine clinic exists (not a survival study). | No individual patient testimonials located for these specific clinics. | Legal and government-reviewed for safety, which is more oversight than most private clinics on this list — but that review does not establish efficacy. |
| Artisan Clinic Hibiya, Tokyo Cancer Clinic, Tokyo Relife Clinic Tokyo, Japan |
artisanclinichibiya.jp 03-6205-8472 tokyocancerclinic.jp +81 3-6380-8031 tokyo-relife.com 0120-660-329 |
Ex vivo expanded, activated NK cells and αβ/γδ T cells, infused for general immune enhancement. | Blood only — not manufactured from tumour tissue | Japan Act on the Safety of Regenerative Medicine | Typical package reported around USD 20,000–50,000. | Same “Advanced Medical Care” classification as above — not covered by Japan’s National Health Insurance or by foreign/international insurance. Fully out-of-pocket. | General immune-activation claims; no glioblastoma-specific outcome data located. | None located for these specific clinics. | Does not meet the “from a tumour sample” criterion — included because it performs NK/T-cell activation, but the product is not tumour-derived or tumour-antigen-specific. |
| Hallwang Private Oncology Clinic Dornstetten, Germany |
hallwang-clinic.com +49 7443 9642 40 |
Dendritic-cell, NK-cell and T-cell activation strategies alongside a broader personalised-oncology programme. | Blood and/or tumour material, varies by protocol (not independently confirmed) | German individual healing attempt | Reported in the ~USD 100,000–127,000 range for a 1–3 week programme in documented cases, with an 80% deposit required upfront before treatment begins. | The clinic states plainly it has no contracts with any statutory or private health insurance company and is not supported by charities or foundations — costs must be settled directly by the patient, no insurance billing pathway offered at all. | No peer-reviewed glioblastoma outcome data located for this clinic specifically; the clinic does not publish outcome/survival data. | Clinic-published testimonials — not glioblastoma-specific, not independently verified. | ⚠ Independent reporting (Science-Based Medicine, others) has specifically named this clinic for selling unproven and ineffective therapies alongside legitimate ones — and GoFundMe banned fundraisers for Hallwang treatment in 2019. Scrutinise closely. |
| Issels Immuno-Oncology Santa Barbara, CA (US) & Tijuana, Mexico |
issels.com +1 (805) 962-2126 |
Autologous dendritic-cell vaccine + lymphokine-activated killer (LAK) cells + activated NK cells, within a broader “integrative” protocol. | Blood and/or tumour material, varies by protocol (not independently confirmed) | US site offers non-cellular integrative services only; the cell-therapy component is delivered at the Tijuana, Mexico site, outside FDA oversight | ~USD 49,800 for a 3-week Integrative Immunotherapy Programme (published price). | Not billed directly to insurance; the clinic provides itemised invoices/codes patients can submit for possible out-of-network reimbursement, but coverage is not guaranteed and depends entirely on the individual plan. | No peer-reviewed glioblastoma outcome data located. | 40+ clinic-published video testimonials — not glioblastoma-specific, not independently verified. | Cell therapy bundled with a wider array of non-cellular “integrative” treatments; get a precise, itemised description of exactly what cell product is made and from what starting material. |
| Hope4Cancer Institute Rosarito, Mexico |
hope4cancer.com +1 (619) 669-6511 |
Proprietary branded protocols (hyperthermia, “SonoPhoto Dynamic Therapy,” proprietary vaccines) marketed for glioblastoma among other cancers. | Not clearly documented as tumour-tissue-derived cell manufacturing | Operates outside FDA oversight (Mexico) | ~USD 45,000–60,000 for the standard 3-week programme (lodging, meals, and a 3-month home programme included) — varies by individual protocol. | Cannot directly process US insurance claims (treatment centre is in Mexico). PPO plans with out-of-country/out-of-network benefits sometimes reimburse partially if pre-verified; HMO plans typically won’t. The clinic explicitly disclaims any guarantee of coverage or reimbursement. | No peer-reviewed outcome data located; marketing material only. | “Aaron” — stage IV glioblastoma story — clinic-published, not independently verified. Weigh this single account against the complete absence of peer-reviewed data. | ⚠ Weakest match to “cell manufacturing” on this list — branding emphasises proprietary alternative-medicine protocols rather than a characterised, verifiable cell product. Lowest confidence of the group. |
Not options now (they require prior standard therapy and disease progression), but worth knowing about if the tumour ever recurs. US sites, adult, immunotherapy or EGFR-targeted. Not exhaustive.
| Trial | NCT | Mechanism | Lead site(s) |
|---|
DKFZ (the German Cancer Research Center) is a research institute, not itself a treating hospital — it is the group that defined the RTK II methylation class this dashboard is built around, and its clinical partner, Heidelberg University Hospital’s Neuro-Oncology programme / NCT Heidelberg, runs its glioma trials. Both DKFZ/Heidelberg trials found for this case are closed — listed below for context, not as open options. Contact NCT Heidelberg directly to ask what is currently recruiting; a search cannot substitute for that.
| Trial | What it is | Reported so far | Why it matters here |
|---|---|---|---|
| SURVIVE / SurVaxM NCT05163080 |
Survivin peptide vaccine + standard temozolomide, newly diagnosed GBM. Randomised phase 2b, ~247 patients, 11 US sites. | Phase 2a: 1-year OS 93.7%, median PFS 11.4 mo, median OS 25.9 mo. Phase 2b passed interim futility; data cut-off reached Jul 2026, randomised readout pending. | Fully accrued — not open. If the randomised result is positive it could reach patients via approval or expanded access. Survivin is broadly expressed in GBM regardless of subtype. |
| DCVax-L (Northwest Biotherapeutics) |
Autologous tumour-lysate dendritic-cell vaccine added to standard care, newly diagnosed and recurrent GBM. Phase 3 with external controls. | Median OS 19.3 mo (ITT); in MGMT-methylated patients 30.2 vs 21.3 mo. Not FDA-approved; methodology debated. | Closest a dendritic-cell vaccine has come to a positive phase 3. Available in some countries / possible compassionate use; ask the treating team. |
| Toca 511 + Toca FC (“Toca 5”) |
Retroviral replicating vector (cytosine deaminase) + oral 5-fluorocytosine, recurrent HGG. Randomised phase 3. | Negative — no overall-survival benefit vs standard of care. | The predecessor of DB107-RRV (listed above). Tempers expectations for that reformulated newly-diagnosed attempt. |
| GAPVAC-101 NCT02149225 Heidelberg & Tübingen, Germany (DKFZ / DKTK, led by Wolfgang Wick) |
Fully personalized dual peptide vaccine (APVAC1 + APVAC2) selected per-patient from whole-exome sequencing + HLA-ligandome analysis, newly diagnosed GBM. Phase I feasibility, integrated into standard of care. | 16 patients enrolled; median PFS 14.2 months and OS 29 months from diagnosis in the 15 who received ≥1 vaccination. Proof-of-concept for personalized-antigen vaccination. | The DKFZ/Heidelberg group that defined the RTK II methylation classification also ran this trial — directly relevant lineage, but it closed after a small Phase I cohort; no larger confirmatory trial has followed. |
| NeoVax + radiotherapy + pembrolizumab NCT02287428 Dana-Farber & Massachusetts General, Boston MA |
Personalized neoantigen synthetic-long-peptide vaccine (up to ~20 peptides + poly-ICLC), newly diagnosed GBM. Phase 1, 39 enrolled (37 initiated, 35 completed priming). | MGMT-methylated subgroup: median OS 36.9 months vs 25.3 months in propensity-matched institutional standard-of-care controls (ASCO 2026). Well tolerated, no serious vaccine-related adverse events. Methylated patients received standard temozolomide + NeoVax priming, with pembrolizumab added after priming. | Directly relevant now that this case is confirmed MGMT-methylated (11 Sep 2026) — this is the most specific outcome data in this whole page for this exact biomarker combination. Not itself open (active, not recruiting) and not a personalized-peptide-vaccine program this US/immunotherapy dashboard otherwise tracks — full detail in the companion atlas. Ask Dana-Farber Center for Neuro-Oncology about a successor trial. |
| N²M² / NOA-20 NCT03158389 13 German NOA sites, led by University Hospital Heidelberg |
Umbrella Phase I/IIa trial randomising newly diagnosed, MGMT-unmethylated GBM to one of several molecularly matched targeted therapies (or atezolizumab / asunercept) alongside radiotherapy. | Completed September 2023; 228 patients enrolled across sub-trials. Individual participant data not shared publicly — full results not independently verifiable from the registry record. | Required MGMT-unmethylated status — the same criterion this list excludes for this case. Included here as context on Heidelberg’s programme, not as an open or case-matched option. |